Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?
| Autor: | Sinharib Citgez, Ahmet Erozenci, Cetin Demirdag, Islim Kaleler, Ezel Uslu, Muhammed Fatih Simsekoglu, Bulent Onal, Zübeyr Talat |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Urinary system medicine.medical_treatment Tryptase 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immune system Internal medicine medicine Humans Mast Cells Prospective Studies 030212 general & internal medicine Prospective cohort study Aged Bladder cancer biology business.industry Immunity General Medicine Immunotherapy Middle Aged medicine.disease Mast cell Administration Intravesical medicine.anatomical_structure Urinary Bladder Neoplasms chemistry BCG Vaccine biology.protein Neoplasm Recurrence Local business Histamine |
| Zdroj: | International Journal of Clinical Practice. 75 |
| ISSN: | 1742-1241 1368-5031 |
| DOI: | 10.1111/ijcp.13959 |
| Popis: | BACKGROUND Mast cells play a critical role in cancer-associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) immunotherapy. METHODS In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N-methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed. RESULTS The average age was 56.1 ± 10.5 years in Group 1 and 52.6 ± 9.7 years in Group 2. Fourteen patients had high-grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N-methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N-methylhistamine levels significantly decreased when immunotherapy was terminated (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|